Last updated: March 13, 2026
What is NDC 24979-0160?
NDC 24979-0160 refers to Vyepti (eptinezumab), a monoclonal antibody prescribed for migraine prevention. Approved by the FDA in February 2020, Vyepti is administered via intravenous infusion every three months. It competes within the migraine preventive space alongside drugs like erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality).
Market Overview
Market Size and Growth Trends
The migraine preventive market was valued at approximately $2.1 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 9-11% through 2028, driven by increasing diagnosis rates, more treatment options, and broader insurance coverage.
Key Pharmacological Competitors
| Drug |
Administration |
Year of Approval |
Market share (2022) |
Estimated Price (per dose) |
| Eptinezumab (Vyepti) |
IV quarterly |
2020 |
15-20% |
$12,750 |
| Erenumab (Aimovig) |
SC monthly |
2018 |
35-40% |
$7,500 |
| Fremanezumab (Ajovy) |
SC monthly or quarterly |
2018 |
20-25% |
$6,900 |
| Galcanezumab (Emgality) |
SC monthly |
2018 |
15-20% |
$7,050 |
Revenue Estimates (2022-2025)
| Year |
Estimated Revenue (USD Billions) |
Notes |
| 2022 |
~$400 million |
Market penetration, ongoing adoption |
| 2023 |
~$600 million |
Expanded insurance coverage, new prescribers |
| 2024 |
~$900 million |
Increased patient access, competition stability |
| 2025 |
~$1.2 billion |
Greater market penetration, pricing pressures |
Price Projections
Current Pricing
Vyepti's price per dose is approximately $12,750, aligning with other IV monoclonal antibodies.
Future Pricing Trends
Price modulation depends on insurance negotiations, competitive landscape, and manufacturing costs. Generally, specialty drugs see modest discounts with increased volume and biosimilar entries—though biosimilar competition is limited for monoclonal antibodies due to patent protections and complexity of manufacturing.
- 2023-2025: Price expected to stay within $12,000-$13,000 per dose.
- Post-2025: Introduction of biosimilars could lead to discounts up to 20-30%, potentially lowering the price to ~$9,000-$10,000.
Factors Affecting Price Trends
- Patent expirations: Patent for eptinezumab is expected to extend into 2035.
- Market competition: Erenumab, fremanezumab, and galcanezumab hold significant market share, constraining price increases.
- Pricing negotiations: Payor pressure could lead to rebates, affecting net prices.
Market Challenges and Opportunities
Challenges
- Limited administration route (IV) compared to SC options, impacting patient convenience.
- Reimbursement barriers in some markets.
- Slow uptake due to prescription inertia and physician familiarity with existing options.
Opportunities
- Growing preference for IV infusions in specialized settings.
- Expanding indications beyond migraine prevention, if approved for other neurological conditions.
- Increasing awareness and diagnosis rates of migraines.
Regulatory and Policy Impacts
- Pricing regulations: US federal policy discussions may impact drug pricing strategies.
- Reimbursement landscape: Insurance coverage expansion enhances adoption but can cap pricing.
Summary of Key Data Points
| Data Point |
Details |
| Market size (2022) |
$2.1 billion |
| CAGR (2022-2028) |
9-11% |
| Estimated market share (2022) |
15-20% (Vyepti) |
| Price per dose (2022) |
$12,750 |
| Revenue projection (2025) |
~$1.2 billion |
Key Takeaways
- NDC 24979-0160 (Vyepti) holds a niche in the migraine prevention market with steady growth expected.
- Its IV administration limits adoption compared to SC competitors but may attract specialized patient segments.
- Price will likely remain stable through 2025, with potential discounts after patent expiration or biosimilar entry.
- Market growth driven by increasing migraine diagnosis and expanding clinical use.
- Competitive pressures necessitate ongoing pricing and access negotiations.
FAQs
1. How does Vyepti compare to other migraine preventives in efficacy?
Vyepti has demonstrated comparable efficacy to SC monoclonal antibodies, with a favorable safety profile. The IV route may offer convenience for healthcare-delivered treatments but limits at-home use.
2. What factors influence Vyepti's future pricing?
Pricing will be affected by biosimilar development, insurance negotiations, manufacturing costs, and regulatory policies.
3. When are biosimilars for eptinezumab expected?
Biologics generally face biosimilar entry 10-12 years post-approval; eptinezumab's patent extends into 2035, delaying biosimilar competition.
4. How is the market share for Vyepti expected to evolve?
Market share growth depends on the clinician preference for IV infusion, patient acceptance, and reimbursement policies. It could reach 25-30% over five years.
5. What impact could new indications have on Vyepti’s market?
Approval for additional neurological or chronic pain indications could expand its market and justify pricing strategies.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] FDA. (2020). Vyepti (eptinezumab) approval letter.
[3] EvaluatePharma. (2022). Global migraine market report.
[4] CVS Health. (2023). Drug pricing trends.
[5] Statista. (2023). Neurology drug market projections.
